MARK RONCONE: Open Payments
NPI 1669982872 · HAGERSTOWN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$564 in 37 payments from 10 companies in 2025. Trend: 2023 $419 · 2024 $662 · 2025 $564
Food & beverage: $564
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $217 |
| Novo Nordisk Inc | 5 | $100 |
| Axsome Therapeutics, Inc. | 3 | $64 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $57 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| AstraZeneca Pharmaceuticals LP | 1 | $22 |
| Cranial Technologies, Inc | 1 | $20 |
| GlaxoSmithKline, LLC. | 1 | $20 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
Products named: VRAYLAR, QULIPTA, Ozempic, Auvelity, CAPLYTA, ABILIFY MAINTENA, AIRSUPRA, Doc Band.
Industry payments across MD — which companies pay providers there.
